Biotech Values

[genisi]

9. Novel Diabetes Therapy: SGLT2 Inhibitors [e.g. BMY/AZN’s dapagliflozin]

In addition to the point you posted in #msg-64636960, another indication that dapagliflozin might not have been the cause of the imbalance in bladder and breast cancers is the lack of such adverse events in individuals carrying mutations in the SLC5A2 gene, encoding a defected SGLT2 protein (which cause increased glucose excretion).